Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly.
Ignacio BernabéuCarmen FajardoMónica MarazuelaFernando CordidoEva María VenegasPedro de Pablos-VelascoGonzalo Piedrola MarotoMaría Pilar OlveraIsabel Pavón de PazDavide CarvalhoCarme RomeroGuillermo De la CruzCristina Álvarez EscoláPublished in: Endocrine (2020)
Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs.